Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation · 2009
Tamoxifen therapy in kidney-transplant patients presenting with severe encapsulating peritoneal sclerosis after treatment for acute humoral rejection.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mohamed Abdellatif Ould, Kamar Nassim, Nogier Marie-Béatrice, Esposito Laure, Duffas Jean Pierre, Rostaing Lionel
Аннотация
OBJECTIVES: Encapsulating peritoneal sclerosis is a rare but serious complication in patients undergoing peritoneal dialysis. Its mortality rate is approximately 30%, despite treatment with total parenteral nutrition, surgery, tamoxifen, or immunosuppressants.
MATERIALS AND METHODS: Of 991 kidney transplants performed at our institution over 9 years, 50 patients were treated for chronic peritoneal dialysis at the time of transplant.
RESULTS: Two cases of encapsulating, peritoneal sclerosis occurred in patients receiving pretransplant peritoneal dialysis. Both had received intensive posttransplant treatment for acute humoral rejection. Encapsulating peritoneal sclerosis occurred at 3 months and 4 months after the transplant. Both presented with intestinal pain and gut obstruction. They were given total parenteral nutrition plus tamoxifen (20 mg/d) for 3 months. Outcomes were favorable for 1, though there was no improvement for the second patient, who was then also given sirolimus. He died later from multiorgan failure secondary to digestive-related sepsis, and encapsulating, peritoneal, sclerosis-related symptoms.
CONCLUSIONS: When encapsulating, peritoneal sclerosis occurs after kidney transplant, tamoxifen therapy could be implemented.
MATERIALS AND METHODS: Of 991 kidney transplants performed at our institution over 9 years, 50 patients were treated for chronic peritoneal dialysis at the time of transplant.
RESULTS: Two cases of encapsulating, peritoneal sclerosis occurred in patients receiving pretransplant peritoneal dialysis. Both had received intensive posttransplant treatment for acute humoral rejection. Encapsulating peritoneal sclerosis occurred at 3 months and 4 months after the transplant. Both presented with intestinal pain and gut obstruction. They were given total parenteral nutrition plus tamoxifen (20 mg/d) for 3 months. Outcomes were favorable for 1, though there was no improvement for the second patient, who was then also given sirolimus. He died later from multiorgan failure secondary to digestive-related sepsis, and encapsulating, peritoneal, sclerosis-related symptoms.
CONCLUSIONS: When encapsulating, peritoneal sclerosis occurs after kidney transplant, tamoxifen therapy could be implemented.
Предметные рубрики MeSH
Acute DiseaseAdultCombined Modality TherapyDrug Therapy, CombinationFatal OutcomeGraft RejectionHumansImmunity, HumoralImmunosuppressive AgentsKidney TransplantationMaleMiddle AgedMultiple Organ FailureParenteral Nutrition, TotalPeritoneal Dialysis, Continuous AmbulatoryPeritoneal FibrosisPlasmapheresisSeverity of Illness IndexTamoxifenTreatment Outcome